Enveric plans to spin off cannabinoid unit Akos Biosciences to shareholders
Enveric Biosciences stock rose 2.3% in premarket trades on Monday after the company said it submitted a confidential form S-1 draft registration statement with the U.S. Securities and Exchange Commission for the spin-off of its cannabinoid clinical development pipeline to a wholly-owned subsidiary, Akos Biosciences Inc. The spinoff will take place in the form of a dividend to Enveric shareholders. Enveric Biosciences CEO Joseph Tucker said the company believes the spin-off will unlock the value... Читать дальше...